GHRS

NASDAQStock

GH Research PLC

$14.77-0.75 (-4.83%)

52-Week Range

$8.66

$19.50

Key Stats

Market Cap

916.2M

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.00

Volume

70.3K

Avg Volume

246.8K

Performance

+2.44%

+24.31%

+18.38%

YTD

+17.22%

+42.65%

+79.42%

-19.38%

Price Chart

ETF Exposure

GHRS is held by 7 ETFs

ETF	Fund Name	Weight	Shares	Market Value	Fund AUM	Expense Ratio
PSIL	AdvisorShares Psychedelics ETF	6.07%	79,334	$1.3M	$20.4M	1.84%
EIRL	iShares MSCI Ireland ETF	1.12%	56,397	$901K	$81.6M	0.50%
BBC	Virtus Biotech Clinical Trials ETF	0.90%	22,152	$349K	$39.0M	0.65%
IBBQ	Invesco Nasdaq Biotechnology ETF	0.07%	3,456	$54K	$74.5M	0.19%
IBB	iShares Biotechnology ETF	0.06%	331,665	$5.2M	$8.50B	0.44%
BIB	ProShares - Ultra Nasdaq Biotechnology	0.05%	2,784	$44K	$86.8M	1.19%
GWX	State Street SPDR S&P International Small Cap ETF	0.02%	11,049	$170K	$865.1M	0.40%

About GHRS ETF Exposure

GH Research PLC (GHRS) is held by 7 exchange-traded funds, making it one of the stocks with significant ETF exposure. With a market capitalization of 916.2M, GHRS is a widely held institutional stock. The stock currently trades at $14.77. Investors can gain exposure to GHRS through a variety of ETFs with different expense ratios, investment strategies, and portfolio weightings. The table above shows all ETFs that currently hold GHRS, sorted by portfolio weight.